Synergetic B-cell Immodulation in SLE

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

Rituximab with belimumab

Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.

Trial Locations (1)

2333 ZA

LUMC, Leiden

All Listed Sponsors
collaborator

Dutch Kidney Foundation

OTHER

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Leiden University Medical Center

OTHER

NCT02284984 - Synergetic B-cell Immodulation in SLE | Biotech Hunter | Biotech Hunter